JP2003528880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003528880A5 JP2003528880A5 JP2001570667A JP2001570667A JP2003528880A5 JP 2003528880 A5 JP2003528880 A5 JP 2003528880A5 JP 2001570667 A JP2001570667 A JP 2001570667A JP 2001570667 A JP2001570667 A JP 2001570667A JP 2003528880 A5 JP2003528880 A5 JP 2003528880A5
- Authority
- JP
- Japan
- Prior art keywords
- carbons
- carbon atoms
- alkyl
- embedded image
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 description 648
- -1 nitro, carboxy Chemical group 0.000 description 347
- 125000000217 alkyl group Chemical group 0.000 description 192
- 229910052757 nitrogen Inorganic materials 0.000 description 132
- 125000003118 aryl group Chemical group 0.000 description 112
- 229910052799 carbon Inorganic materials 0.000 description 108
- 125000003342 alkenyl group Chemical group 0.000 description 96
- 125000003545 alkoxy group Chemical group 0.000 description 96
- 125000000304 alkynyl group Chemical group 0.000 description 96
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 84
- 125000005042 acyloxymethyl group Chemical group 0.000 description 72
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 72
- 125000004181 carboxyalkyl group Chemical group 0.000 description 72
- 229910052736 halogen Inorganic materials 0.000 description 72
- 150000002367 halogens Chemical class 0.000 description 72
- 125000004970 halomethyl group Chemical group 0.000 description 72
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 72
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 72
- 125000004093 cyano group Chemical group *C#N 0.000 description 61
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 60
- 125000005236 alkanoylamino group Chemical group 0.000 description 60
- 125000003282 alkyl amino group Chemical group 0.000 description 60
- 125000004414 alkyl thio group Chemical group 0.000 description 60
- 125000004103 aminoalkyl group Chemical group 0.000 description 60
- 150000001540 azides Chemical class 0.000 description 60
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 60
- 150000001721 carbon Chemical group 0.000 description 60
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 60
- 125000001424 substituent group Chemical group 0.000 description 60
- 125000004849 alkoxymethyl group Chemical group 0.000 description 48
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 48
- 125000004663 dialkyl amino group Chemical group 0.000 description 48
- 125000004043 oxo group Chemical group O=* 0.000 description 48
- 125000004076 pyridyl group Chemical group 0.000 description 48
- 125000000714 pyrimidinyl group Chemical group 0.000 description 48
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 48
- 150000003839 salts Chemical class 0.000 description 46
- 229910052739 hydrogen Inorganic materials 0.000 description 42
- 239000001257 hydrogen Substances 0.000 description 42
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 36
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 36
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 36
- 229910052717 sulfur Inorganic materials 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 35
- 208000035269 cancer or benign tumor Diseases 0.000 description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 27
- 125000004754 (C2-C12) dialkylamino group Chemical group 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 24
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 24
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 24
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 24
- 239000003610 charcoal Substances 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 24
- 125000000753 cycloalkyl group Chemical group 0.000 description 24
- 125000005842 heteroatom Chemical group 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 24
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 24
- 230000037361 pathway Effects 0.000 description 16
- 0 CC(C)OC(*)(C(C)([*@@](C)C(C)=*C)N)O Chemical compound CC(C)OC(*)(C(C)([*@@](C)C(C)=*C)N)O 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 12
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 12
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 12
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 12
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 12
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 12
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 12
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 12
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 12
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 12
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
- 229910052794 bromium Inorganic materials 0.000 description 12
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- 125000004430 oxygen atom Chemical group O* 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 239000011593 sulfur Substances 0.000 description 12
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 12
- 150000003536 tetrazoles Chemical class 0.000 description 12
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 12
- 229930192474 thiophene Natural products 0.000 description 12
- 239000003937 drug carrier Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 8
- CIIFKVFOVFJZDM-UHFFFAOYSA-N quinoline-8-carbonitrile Chemical compound C1=CN=C2C(C#N)=CC=CC2=C1 CIIFKVFOVFJZDM-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 2
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 2
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 2
- 101150093908 PDGFRB gene Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- SUMGLCJBKVZIGT-UHFFFAOYSA-N 9-(2,4-dichloroanilino)-3,4-dihydro-2h-pyrido[2,3-g][1,4]benzoxazine-8-carbonitrile Chemical compound ClC1=CC(Cl)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CC1=C2OCCN1 SUMGLCJBKVZIGT-UHFFFAOYSA-N 0.000 description 1
- PNBHVECJNWQWBD-UHFFFAOYSA-N 9-(2,4-dichloroanilino)-4-[4-(4-ethylpiperazin-1-yl)butyl]-2,3-dihydropyrido[2,3-g][1,4]benzoxazine-8-carbonitrile Chemical compound C1CN(CC)CCN1CCCCN1C2=CC3=NC=C(C#N)C(NC=4C(=CC(Cl)=CC=4)Cl)=C3C=C2OCC1 PNBHVECJNWQWBD-UHFFFAOYSA-N 0.000 description 1
- KATHFODQQRANKE-UHFFFAOYSA-N 9-(3-chloro-4-fluoroanilino)-2,3-dihydro-1h-pyrido[3,2-g][1,4]benzoxazine-8-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=C(C#N)C=NC1=CC1=C2NCCO1 KATHFODQQRANKE-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000020086 Ephrin-A1 Human genes 0.000 description 1
- 108010043945 Ephrin-A1 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53691900A | 2000-03-28 | 2000-03-28 | |
| US09/536,919 | 2000-03-28 | ||
| PCT/US2001/010124 WO2001072758A1 (en) | 2000-03-28 | 2001-03-28 | Tricyclic protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528880A JP2003528880A (ja) | 2003-09-30 |
| JP2003528880A5 true JP2003528880A5 (https=) | 2008-05-22 |
Family
ID=24140461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570667A Pending JP2003528880A (ja) | 2000-03-28 | 2001-03-28 | 三環系タンパクキナーゼ阻害薬 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1268487B1 (https=) |
| JP (1) | JP2003528880A (https=) |
| CN (1) | CN100369919C (https=) |
| AR (1) | AR028261A1 (https=) |
| AT (1) | ATE255114T1 (https=) |
| AU (1) | AU2001247882A1 (https=) |
| BR (1) | BR0109598A (https=) |
| CA (1) | CA2404445A1 (https=) |
| DE (1) | DE60101323T2 (https=) |
| MX (1) | MXPA02009440A (https=) |
| WO (1) | WO2001072758A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| BRPI0413018B8 (pt) | 2003-07-30 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, e, uso de um composto |
| KR20070011458A (ko) | 2004-04-08 | 2007-01-24 | 탈자진 인코포레이티드 | 키나제의 벤조트리아진 억제제 |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| JP5461402B2 (ja) * | 2007-09-14 | 2014-04-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換三環式化合物およびその使用方法 |
| US8309566B2 (en) | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| MX2010011463A (es) | 2008-04-16 | 2011-06-03 | Portola Pharm Inc | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. |
| NZ588830A (en) | 2008-04-22 | 2012-11-30 | Portola Pharm Inc | Inhibitors of protein kinases |
| WO2012006960A1 (en) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
| CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CA3094793A1 (en) | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2712290A1 (fr) * | 1993-11-10 | 1995-05-19 | Pf Medicament | Oxazino-acridines substituées, leur préparation et leur application en thérapeutique. |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
-
2001
- 2001-03-16 AR ARP010101252A patent/AR028261A1/es unknown
- 2001-03-28 CA CA002404445A patent/CA2404445A1/en not_active Abandoned
- 2001-03-28 JP JP2001570667A patent/JP2003528880A/ja active Pending
- 2001-03-28 EP EP01920873A patent/EP1268487B1/en not_active Expired - Lifetime
- 2001-03-28 AU AU2001247882A patent/AU2001247882A1/en not_active Abandoned
- 2001-03-28 WO PCT/US2001/010124 patent/WO2001072758A1/en not_active Ceased
- 2001-03-28 BR BR0109598-6A patent/BR0109598A/pt not_active Application Discontinuation
- 2001-03-28 AT AT01920873T patent/ATE255114T1/de not_active IP Right Cessation
- 2001-03-28 CN CNB018072011A patent/CN100369919C/zh not_active Expired - Fee Related
- 2001-03-28 DE DE60101323T patent/DE60101323T2/de not_active Expired - Lifetime
- 2001-03-28 MX MXPA02009440A patent/MXPA02009440A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003528880A5 (https=) | ||
| US11267802B2 (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| JP2005504080A5 (https=) | ||
| RU2006147237A (ru) | Производные пирролотриазина, применение для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом | |
| CA3028997A1 (en) | 2,4-diamino-pyrimidine compounds and method for making and using the compounds | |
| JP2012501312A5 (https=) | ||
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2003511384A5 (https=) | ||
| RU2003116061A (ru) | Тиоэфирзамещенные имидазохинолины | |
| WO2007109334B1 (en) | Sip receptor modulating compounds and use thereof | |
| CA2545527A1 (en) | Pyrazole derivatives as inhibitors of receptor tyrosyne kinases | |
| JP2012520269A5 (https=) | ||
| JP2004525965A5 (https=) | ||
| JP2005508953A5 (https=) | ||
| JP2017530139A (ja) | 未分化リンパ腫キナーゼの多環状阻害剤 | |
| JP2017501983A5 (https=) | ||
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| JP2012518598A5 (https=) | ||
| JP2005513020A5 (https=) | ||
| RU2299205C2 (ru) | Средство против кислотоустойчивых бактерий, содержащее пиридонкарбоновые кислоты в качестве активного компонента | |
| ES2939232T3 (es) | Derivados de oxazol para uso como inhibidores de IRAK y método para su preparación | |
| JP6250062B2 (ja) | がん、ウイルス感染症、及び肺疾患の処置のためのインドールの新規誘導体 | |
| JP4272056B2 (ja) | アリールピペラジンに連結したテトラヒドロインドロン及びプリン誘導体 | |
| JP7763538B2 (ja) | Ｐａｒｐ７阻害剤及びその使用 |